ACS Infectious Diseases · 2019 · 34 citations · 42 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationAntibacterial PharmacologyAntibiotic ResistanceEnzyme InhibitionHit-to-lead OptimizationTopoisomerase InhibitorsAntibiotic DiscoveryMethicillin-resistant Staphylococcus Aureus Infection TreatmentMethicillin-resistant Staphylococcus Aureus TreatmentNovel Antibacterial Drug DiscoveryTopoisomerase Activity
(MRSA) is needed to counteract the significant threat that MRSA presents to human health. Novel inhibitors of DNA gyrase and topoisomerase IV (TopoIV) constitute one highly promising approach, but continued optimization is required to realize the full potential of this class of antibiotics. Herein, we report further studies on a series of dioxane-linked derivatives, demonstrating improved antistaphylococcal activity and reduced hERG inhibition. A subseries of analogues also possesses enhanced inhibition of the secondary target, TopoIV.
42
Evelina Tacconelli, Elena Carrara, Alessia Savoldi et al. · The Lancet Infectious Diseases · 2017 · 6.1K citations · Full text
High-Resolution Comparative Modeling with RosettaCM
Yifan Song, Frank DiMaio, Ray Yu‐Ruei Wang et al. · Structure · 2013 · 1.2K citations · Full text
Domain enhanced lookup time accelerated BLAST
Grzegorz M. Boratyn, Alejandro A. Schäffer, Richa Agarwala et al. · Biology Direct · 2012 · 863 citations · Full text
Type IIA topoisomerase inhibition by a new class of antibacterial agents
B.D. Bax, Pan F. Chan, Drake S. Eggleston et al. · Nature · 2010 · 842 citations